Search

Displaying results 5321 - 5330 of 5925 in total
  1. Drug

    Norclobazam

    go.drugbank.com/drugs/DB17092
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  2. Drug

    Redaporfin

    go.drugbank.com/drugs/DB17219
    Investigational

    Categories: P-glycoprotein substrates
  3. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  4. Drug

    CY-1503

    go.drugbank.com/drugs/DB17605
    Investigational

    CY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl

  5. Drug

    Allopurinol riboside

    go.drugbank.com/drugs/DB17738
    Experimental

    Allopurinol riboside is a nucleoside analogue of [allopurinol] with a beta-D-ribofuranosyl moiety at the 1-position.

    Synonyms: 4h-pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-1-.beta.-d-ribofuranosyl-
  6. Drug

    EF-022

    go.drugbank.com/drugs/DB17768
    Investigational

    EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.

    Synonyms: Modified vitamin D binding protein, Modified Vitamin D Binding Protein Macrophage Activator
  7. Drug

    Linafexor

    go.drugbank.com/drugs/DB18031
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Gunagratinib

    go.drugbank.com/drugs/DB18191
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. On October 7, 2025, nerandomilast was approved as the first new treatment for idi...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    ACTX-401

    go.drugbank.com/drugs/DB18504
    Experimental

    ACTX-401 is a single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing the human immunoglobulin u-binding protein 2 cDNA.